Survey of Ophthalmology
Volume 49, Issue 2, Supplement 2 , Pages S55-S61 , March 2004

Reducing the risk of postoperative endophthalmitis

  • Randall J. Olson, MD

      Affiliations

    • Corresponding Author InformationReprint address: Randall Olson, MD, John A. Moran Eye Center, University of Utah School of Medicine, 50 N. Medical Drive, Salt Lake City, Utah, 84132.

References 

  1. Aaberg TM, Flynn HW, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998;105:1004–1010
  2. Akkan AG, Mutlt I, Ozyazgan S. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor of the uninflamed eye. J Chemotherapy. 1997;9:257–262
  3. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  4. Allen HF, Mangiaracine AB. Bacterial endophthalmitis after cataract extraction. Arch Ophthalmol. 1974;91:3–7
  5. Allen HF, Mangiaracine AB. Bacterial endophthalmitis after cataract extraction. A study of 22 infections in 20,000 operations. Arch Ophthalmol. 1964;72:454–462
  6. Apt L, Isenberg SJ, Yoshimori R, Spierer A. Outpatient topical use of povidone-iodine in preparing the eye for surgery. Ophthalmology. 1989;96:289–292
  7. Beck R, van Keyserlingk J, Fischer U. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. Graefes Arch Clin Exp Ophthalmol. 1999;237:89–92
  8. Callahan A. Effect of sulfonamides and antibiotics on panophthalmitis complicating cataract extraction. Arch Ophthalmol. 1953;49:212–219
  9. Callegan MC, Englebert M, Parke DW. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15:111–124
  10. Chaudry NA, Flynn HW, Murray TG. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509–510
  11. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109:13–26
  12. Colleaux KM, Hamilton WK. Effect of prophylactic antibiotics and incision type on the incidence of endophthalmitis after cataract surgery. Can J Ophthalmol. 2000;35:373–378
  13. Dickey JB, Thompson KD, Jay WM. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol. 1991;112:278–282
  14. Doft BM, Kelsey SF, Wisniewski SR. Retinal detachment in the endophthalmitis vitrectomy study. Arch Ophthalmol. 2000;118:1661–1665
  15. Donnenfeld ED, Schrier A, Perry HD. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology. 1994;101:902–905
  16. Dunnington JH, Locatcher-Khorazo D. Value of cultures before operation for cataract. Arch Ophthalmol. 1945;34:215–219
  17. Egger SF, Huber-Spitzy V, Scholda C. Bacterial contamination during extracapsular cataract extraction: prospective study on 200 consecutive patients. Ophthalmologica. 1994;208:77–81
  18. Eifrig CW, Flynn HW, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes (1995–2001). Ophthalmic Surg Lasers. 2002;33:373–378
  19. Endophthalmitis Vitrectomy Study Group . Microbiologic factors and visual outcomes in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122:830–846
  20. Endophthalmitis Vitrectomy Study Group . Results of the endophthalmitis vitrectomy study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–1496
  21. Fisch A, Salvanet A, Prazuck T. Epidemiology of infective endophthalmitis in France. Lancet. 1991;338:1373–1378
  22. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1649–1653
  23. Fung-Tomc J, Gradelski E, Huczko E. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants. Int J Antimicrob Agents. 2001;18:77–80
  24. Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313–1318
  25. Han DP, Wisniewski SR, Wilson LA. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1–17 [Erratum in Am J Ophthalmol 122:920, 1996]
  26. Hanioglu-Kargi S, Basci N, Soysal H. The penetration of ofloxacin into human aqueous humor given by various routes. Eur J Ophthalmol. 1998;8:33–36
  27. Hughes WF, Owens WC. Postoperative complications of cataract extraction. Arch Ophthalmol. 1947;38:577–589
  28. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery (IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic). Arch Ophthalmol. 1985;103:1340–1342
  29. Javitt JC, Street DA, Tielsch JM. National outcomes of cataract extraction and endophthalmitis after outpatient cataract surgery. Cataract patient outcomes research team. Ophthalmology. 1994;101:100–105
  30. Kattan HM, Flynn HW, Pflugfelder SC. Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology. 1991;98:227–238
  31. Kobayakawa S, Tochikubo T, Tsuji A. Penetration of levofloxacin into human aqueous humor. Ophthalmic Res. 2003;35:97–101
  32. Kumar R, Reeves DL, Olson RJ. Wound complications associated with incision enlargement when placing foldable intraocular lenses during cataract surgery. J Cataract Refract Surg. 2002;27:224–226
  33. Lehmann OJ, Roberts CJ, Ikram K. Association between nonadministration of subconjuctival cefuroxime and postoperative endophthalmitis. J Cataract Refract Surg. 1997;23:889–893
  34. Liesegang TJ. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol. 2001;12:68–74
  35. Locatcher-Khorazo D, Gutierriez E. Eye infections following catarct extraction with special reference to the role of Staphylococcus Aureus. Am J Ophthalmol. 1956;41:981–987
  36. Mamalis N, Kearsley L, Brinton E. Postoperative endophthalmitis. Curr Opin Ophthalmol. 2002;13:14–19
  37. Masket S. Preventing, diagnosing, and treating endophthalmitis. J Cataract Refract Surg. 1998;24:725–726
  38. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463–466
  39. Montan PG, Koranyi G, Setterquist HE. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology. 1998;105:2171–2177
  40. Montan PG, Setterquist H, Marcusson E. Preoperative gentamicin eye drops and chlorhexidine solution in cataract surgery. Experimental and clinical results. Eur J Ophthalmol. 2000;10:286–292
  41. Montan PG, Wejde G, Koranyi G. Prophylactic intracameral cefuroxime: efficacy in preventing endophthalmitis after cataract surgery. J Cataract Refract Surg. 2002;28:977–981
  42. Morlet N, Li J, Semmens J, Ng J. The Endophthalmitis Population Study of Western Australia (EPSWA). Br J Ophthalmology. 2003;87:574–576
  43. Nagaki Y, Hayasaka S, Kadoi C. Bacterial endophthalmitis after small-incision cataract surgery: effect of incision placement and intraocular lens type. J Cataract Refract Surg. 2003;29:20–26
  44. Olson RJ. Corneal problems associated with phacoemulsification. In:  Fishkind WJ editors. Complications in Phacoemulsification: Avoidance, Recognition and Management. New York: Thieme New York; 2002;p. 166–181
  45. Prince HN, Nonemaker WS, Norgard RC. Drug resistance studies with topical antiseptics. J Pharmaceutical Sci. 1978;67:1629–1631
  46. Schmitz S, Dick HB, Krummenauer F, Pfeiffer N. Endophthalmitis in cataract surgery: results of a German survey. Ophthalmology. 1999;106:1869–1877
  47. Semmens JB, Li J, Morlet N, Ng J. Trends in cataract surgery and postoperative endophthalmitis in Western Australia (1980–1998): the Endophthalmitis Popoulation Study of Western Australia. Clin Experiment Ophthalmol. 2003;31:213–219
  48. Sherwood DR, Rich WJ, Jacob JS. Bacterial contamination of intraocular and extraocular fluids during extracapsular cataract extraction. Eye. 1989;3:308–312
  49. Somani S, Grinbaum A, Slomovic AR. Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can J Ophthalmol. 1997;32:303–310
  50. Speaker MG, Menikoff J. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769–1775
  51. Speaker MG, Milch FA, Shah MK. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 1991;98:639–649
  52. Starr MB, Lally JM. Antimicrobial prophylaxis for ophthalmic surgery. Surv Ophthalmol. 1995;39:485–501
  53. Ta CN, Egbert PR, Singh K. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002;109:2036–2041
  54. Thomas J, Sims M, Hoffmann C. Intraocular bacterial contamination during sutureless, small incision, single-port phacoemulsification. J Cataract Refract Surg. 2000;26:1786–1791
  55. Versteegh MF, Van Rij G. Incidence of endophthalmitis after cataract surgery in the Netherlands: several surgical techniques compared. Documenta Ophthalmologica. 2000;100:1–6
  56. Yalvac IS, Basci NE, Bozkurt A, Duman S. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refractive Surg. 2003;29:487–491
  57. Yamada M, Mochizuki H, Yamada K. Aqueous humor levels of topically applied levofloxacin in human eyes. Curr Eye Res. 2002;24:403–406
  58. Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg. 1986;151:400–406

☆ The author reported no proprietary or commercial interest in any product mentioned or concept discussed in this article. Dr. Olson is a consultant for Allergan, Inc.

PII: S0039-6257(04)00003-7

doi: 10.1016/j.survophthal.2004.01.002

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 2 , Pages S55-S61 , March 2004

Article Tools